On July 23, 2022, the theme of 'early diagnosis of cancer, focusing on potential - gene methylation detection Summit Forum (Hubei special session)' held by Wuhan amison life science and Technology Co., Ltd. (hereinafter referred to as 'amison') was successfully held in Wuhan.

△ Site map of the Summit Forum (Hubei special session)

Professor Li Yan from the people's Hospital of Wuhan University was invited as the chairman of the forum; Professor Hu Jianhua of Hubei Cancer Hospital, Professor Zhao Youyun of Hubei Hospital of traditional Chinese medicine, and Professor Zhang Xiong of Wuchang hospital served as the presiding guests; Professor Lu Zhongxin, Ph.D. of commercial construction, Department of Gastroenterology, Central South Hospital of Wuhan University and professor of Wuhan Central Hospital, served as lecturers; Professor Xiong liang of Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Professor Wu Shimin of Yangtze River shipping general hospital and Professor Chen Guoqiang of Huanggang central hospital served as the discussion guests. Many Hubei laboratory, clinical and pathological experts gathered together to discuss the new direction and new results of early diagnosis of intestinal cancer.

Professor Li Yan, chairman of the conference, mentioned in his opening speech that early screening and early diagnosis of cancer is the key strategic goal of the state to ensure people's health, and reducing the incidence rate of cancer is the unremitting pursuit of the examiner. There are many methods for early diagnosis of cancer. Among them, gene methylation detection for colorectal cancer is strongly recommended by various guidelines, and relevant products have been published. Therefore, DNA methylation technology is worthy of discussion, exploration and application by peers.

△ Speech by Professor Li Yan

Dr. Shang Jian from the Department of Gastroenterology, Central South Hospital, Wuhan University shared the interpretation of the registered clinical study of the joint detection of methylation of sdc2 and TFPI2 genes for colorectal cancer. Dr. Shang Jian first pointed out that the current early diagnosis rate of colorectal cancer in China is low, and screening efforts need to be strengthened, and fecal DNA methylation detection can effectively help early screening and early diagnosis of colorectal cancer; Central South Hospital of Wuhan University, Beijing Union Medical College Hospital and the First Affiliated Hospital of Anhui Medical University jointly conducted 1438 clinical trials of rectal cancer with different sample stages. As an actual participant, Dr. Shang Jian shared the details of the clinical trials from four perspectives, from the project background to the clinical research path, as well as the output of the experimental results and the expected use of the project. From the perspective of the whole clinical trial participation, The process from zero to one is analyzed in detail. According to the results of the final clinical trial, the overall sensitivity and specificity of the combined detection of sdc2 and TFPI2 gene methylation for colorectal cancer were 95.3%, 90.3%, 63.4% for advanced adenoma and 34.3% for non advanced adenoma, which greatly satisfied the current clinical dilemma of low detection rate of early cancer, better divided the cancer risk population, and improved the level of detection and clinical diagnosis and treatment. Finally, Dr. Shang pointed out that compared with single gene testing, AI Changkang ® It has good detection effect on left and right colon cancer and precancerous lesions, and its detection performance is superior to that of similar products at home and abroad. It is recommended to use sdc2 and TFPI2 dual target fecal DNA methylation kits for colorectal cancer detection before colonoscopy.

△Dr. Shang Jian participated in the Forum

The theme shared by Dr. Zhou Jun, the R & D director of Ameson methylation project, is 'DNA methylation detection methods and Applications'. Dr. Zhou Jun introduced the relevant knowledge of DNA methylation in simple terms from the perspectives of the characteristics, detection methods and clinical applications of DNA methylation. DNA methylation is characterized by universality, heritability, reversibility and tissue specificity; DNA methylation, as an early molecular event of cancer occurrence, can be used in clinic as a molecular marker for early diagnosis of cancer. At present, relevant studies such as nasopharyngeal carcinoma, liver cancer and colorectal cancer have been published, which is more suitable for early screening of cancer than gene mutation.

△Dr. Zhou Jun participated in the Forum

Professor Lu Zhongxin of Wuhan Central Hospital shared the theme of 'guidelines / consensus interpretation on early detection of colorectal cancer'. Professor Lu also pointed out that the current situation of colorectal cancer in China is not optimistic. The state has also issued many documents to support early screening and diagnosis of cancer. Colorectal cancer is a cancer that can be screened internationally. The short-term goal of colorectal cancer screening in China is to improve the screening rate of the population, improve the detection rate of early CRC and important precancerous lesions, and improve the quality of colonoscopy; The medium-term goal is to increase the proportion of early stage cancer in the overall CRC and reduce the incidence rate of screening interphase CRC; The long-term goal is to reduce the mortality and incidence rate of CRC. Professor Lu focused on introducing the changes of relevant early detection methods in the guidelines / consensus for colorectal cancer in China over the past decade: with the younger incidence of colorectal cancer in China, the screening age has been gradually increased from 50 to 40 years; There are many screening methods. Fecal DNA detection based on DNA methylation technology is the best choice for early diagnosis of colorectal cancer at present. It has the advantages of no special equipment, no restriction of diet, no pain and no trauma. It is suitable for Chinese population census. It is suggested that the screening cycle should be once every 1-3 years, and high-quality colonoscopy should be conducted for the positive population.

△Professor Lu Zhongxin participated in the Forum

Dr. Zhang Lianglu, chairman of Ameson, introduced the company's development history and corporate culture concept to the guests. Since its establishment in 2015, the company has always followed the product concept of 'early, accurate, convenient and universal benefit', based on providing better early diagnosis products for all mankind. After years of technical precipitation and R & D accumulation, the company has launched early diagnosis products for digestive tract tumors, gynecological tumors, urinary system tumors and pan cancer species. Based on the doctor's feelings and craftsman's spirit, with the needs of diagnosis and treatment as the center, and striving for innovators as the foundation, amison has concentrated its efforts and gathered momentum, and has won high recognition from industry experts and industry peers.

△Dr. Zhang Lianglu participated in the Forum

After the wonderful academic sharing, under the chairmanship of Professor Zhang Xiong, Professor Xiong Liang, Professor Wu Shimin, Professor Chen Guoqiang, Dr. Zhang Lianglu, the chairman of Ameson, and Professor Li Yan, the chairman of the conference, held a round table discussion, and conducted a series of wonderful questions and answers on 'difficulties and breakdowns of early diagnosis of intestinal cancer'.

△Round table discussion

“癌症早诊，聚势而为—基因甲基化检测高峰论坛（湖北专场）”是艾长康线下学术之旅第一站，也是新的起点。艾米森人将坚持不懈，传递肠癌早诊的新技术新方法新理念，让肿瘤早诊的健康理念普及大众。

发现一例早癌，挽救一条生命，幸福一个家庭！肠癌早诊，艾米森在行动。